SuperworthUnited Therapeutics UTHR
- Market cap
- $25.2B
- PE
- 21.0×
- 10y median 14.1×
- Forward PE
- 22.0×
- 10y median 10.7×
- Price to sales
- 8.0×
- EV/EBIT
- 16.1×
- Revenue, 12 months
- $3.2B
- +2% on a year ago
- Net margin
- 41.6%
- Free cash flow yield
- 4.3%
United Therapeutics trades at 21.0× trailing earnings, pricier than 99% of the last ten years. Revenue was $3.2B over the last twelve months, up 2% on a year earlier with a 42% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $609.4M+18% | $614.7M+25% | $677.7M+34% | $714.9M+20% | $748.9M+23% | $735.9M+20% | $794.4M+17% | $798.6M+12% | $799.5M+7% | $790.2M+7% | $781.5M−2% | $783.3M−2% | |
| Cost of revenue | $70.1M+88% | $71M+21% | $72.9M+39% | $77.8M+21% | $83.1M+19% | $75.9M+7% | $92.5M+27% | $87.6M+13% | $100.9M+21% | $103.4M+36% | $133.4M+44% | $99.5M+14% |
| Gross profit | $539.3M+13% | $543.7M+26% | $604.8M+33% | $637.1M+20% | $665.8M+24% | $660M+21% | $701.9M+16% | $711M+12% | $698.6M+5% | $686.8M+4% | $648.1M−8% | $683.8M−4% |
| R&D | $84.7M+28% | $151.4M+61% | $104.1M+26% | $139.6M+57% | $103.5M+22% | $133.8M−12% | $149M+43% | $134M−4% | $127.5M+23% | $139.5M+4% | $138.2M−7% | $146.3M+9% |
| SG&A | $127.6M+30% | $132.2M−19% | $144.4M+65% | $177.6M+37% | $219.2M+72% | $168.5M+28% | $170.1M+18% | $212.5M+20% | $182.6M−17% | $190.6M+13% | $184.1M+8% | $206.7M−3% |
| $327M+4% | $260.1M+48% | $356.3M+25% | $319.9M+2% | $343.1M+5% | $357.7M+38% | $382.8M+7% | $364.5M+14% | $388.5M+13% | $356.7M−0% | $325.8M−15% | $330.8M−9% | |
| Interest expense | $15.6M+70% | $15.1M+23% | $13.3M−4% | $11.6M−22% | $10.1M−35% | $7.9M−48% | $6.1M−54% | $7.3M−37% | $3M−70% | $3.1M−61% | $3M−51% | $2.9M−60% |
| Pre-tax income | $351.8M+13% | $295.4M+65% | $398.6M+37% | $355.3M+6% | $388.6M+11% | $396.5M+34% | $423.5M+6% | $408.4M+15% | $438M+13% | $444M+12% | $318.3M−25% | $372.7M−9% |
| $84.2M+15% | $78.3M+68% | $92M+80% | $77.2M+2% | $79.5M−6% | $95.2M+22% | $101.3M+10% | $98.9M+28% | $99.3M+25% | $79.7M−16% | $43.4M−57% | $39.7M−60% | |
| Net income | $267.6M+12% | $217.1M+64% | $306.6M+27% | $278.1M+7% | $309.1M+16% | $301.3M+39% | $322.2M+5% | $309.5M+11% | $338.7M+10% | $364.3M+21% | $274.9M−15% | $333M+8% |
| $5.38+10% | $4.34+63% | $6.17+27% | $5.85+12% | $6.39+19% | $6.21+43% | $6.63+8% | $6.41+10% | $7.16+12% | $7.70+24% | $5.82−12% | $7.27+13% | |
| 49.7M+2% | 50M+1% | 49.7M+0% | 47.5M−4% | 48.4M−3% | 48.5M−3% | 48.6M−2% | 48.3M+2% | 47.3M−2% | 47.3M−3% | 47.2M−3% | 45.8M−5% |
Gross profit: 69 periods, Q2 FY09 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 38 periods, Q3 FY11 to Q4 FY22: not printed by the filing, worked out from its own lines.
EPS, diluted: 8 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY09 and Q4 FY13: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 15 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $781.6M | $766.3M to $799.4M | $6.02 | $4.52 to $6.89 | 10 |
| Q4 FY26 | $840.4M | $792.5M to $944.7M | $7.39 | $6.88 to $8.51 | 10 |
| Q1 FY27 | $804.7M | $729.4M to $970.5M | $7.10 | $6.23 to $9.00 | 8 |
| Q2 FY27 | $823.8M | $746.7M to $993.6M | $7.29 | $6.40 to $9.24 | 8 |
| Q3 FY27 | $814.2M | $738M to $982M | $6.92 | $6.07 to $8.77 | 8 |
| Q4 FY27 | $918.3M | $832.4M to $1.1B | $7.78 | $6.83 to $9.86 | 8 |
Peers
Companies in Biotechnology nearest United Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| UTHRUnited Therapeutics | $25.2B | 21.0× | 14.1× | 22.0× | 8.0× | +2% | 41.6% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| ALNYAlnylam Pharmaceuticals | $30B | 37.8× | 69.2× | 26.7× | 6.2× | +95% | 16.8% |
| EXELExelixis | $16B | 20.3× | 22.8× | n/m | 6.6× | +9% | 35.3% |
| ONCBeOne Medicines | $42.9B | 67.6× | 68.4× | 48.1× | 7.0× | +34% | 10.7% |
| NBIXNeurocrine Biosciences | $14.5B | 20.9× | 42.8× | n/m | 4.3× | +34% | 20.9% |
| HALOHalozyme Therapeutics | $14.3B | 37.5× | 21.3× | n/m | 8.6× | +41% | 24.9% |
| TECHBIO-TECHNE | $11.4B | 63.1× | 61.6× | n/m | 9.4× | −0% | 15.0% |
| RGENRepligen | $10B | 242× | 120× | n/m | 12.7× | +16% | 5.3% |
| KRYSKrystal Biotech | $9.2B | 39.0× | 42.7× | n/m | 20.9× | +23% | 54.8% |
| REGNRegeneron Pharmaceuticals | $82.9B | 19.9× | 19.7× | 12.6× | 5.3× | +9% | 27.9% |
| Peer median | $15.2B | 37.6× | 42.8× | 37.4× | 6.8× | +25% | 22.9% |
Investors who own it
Investors we follow who held United Therapeutics at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.2% of portfolioadded
More on United Therapeutics
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #10of 317Healthcare stocks with the highest profit margins
- #3of 29Biotech stocks with the highest profit margins
- #7of 17Biotech stocks with the lowest EV/EBIT
- #8of 18Biotech stocks with the highest free cash flow yield
- #8of 16Biotech stocks with the lowest PE ratio
- #10of 14Biotech stocks with the fastest earnings growth
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .